Centre d Oncologie de Gentilly

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Lung cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Childhood cancers1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial

Phase

• Phase 23 trials
• Phase 41 trial

Status

• Completed5 trials
• Recruiting3 trials

Lead sponsor

• ARCAGY/ GINECO GROUP1 trial
• Centre Paul Strauss1 trial
• European Organisation for Research and Treatment of Cancer - EORTC1 trial
• Federation Francophone de Cancerologie Digestive1 trial
• GFPC Investigation1 trial
• and 3 more

Running trials

• Recruiting

  PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

  NCT06646471· Phase 4· GFPC Investigation· Source

  Contact: Laurene GAVOILLE

• Recruiting

  DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT04920617· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source

  Contact: Thomas Lelu

• Recruiting

  SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

  NCT02834884· European Organisation for Research and Treatment of Cancer - EORTC· Source

  Contact: EORTC HQ

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution

  NCT06379880· Centre Paul Strauss· Source

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Pfizer· Source

• Completed

  UTOLA: UTerin OLAparib

  NCT03745950· Phase 2· ARCAGY/ GINECO GROUP· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source